

Astemizole tetrachlorocobaltate(II)

Masood Parvez

Department of Chemistry, The University of Calgary, 2500 University Drive NW, Calgary, Alberta, Canada T2N 1N4

Correspondence e-mail: parvez@ucalgary.ca

Key indicators

Single-crystal X-ray study

$T = 170$ K

Mean $\sigma(\text{C}-\text{C}) = 0.009$ Å

Disorder in main residue

R factor = 0.065

wR factor = 0.157


Data-to-parameter ratio = 14.3

For details of how these key indicators were automatically derived from the article, see <http://journals.iucr.org/e>.

The structure of {3-[(4-fluorophenyl)methyl]-1*H*-benzimidazol-2-ylidene}{1-[2-(4-methoxyphenyl)ethyl]-4-piperidin-1-yl}ammonium tetrachlorocobaltate(II), $(\text{C}_{28}\text{H}_{33}\text{FN}_4\text{O})\cdot[\text{CoCl}_4]^{2-}$, is isomorphous with its CuCl_4^{2-} analogue. It contains diprotonated cations of astemizole hydrogen-bonded to three Cl atoms in two different CoCl_4^{2-} anions, with $\text{Cl}\cdots\text{N}$ distances in the range 3.109 (5)–3.212 (5) Å. One of the Cl atoms in the CoCl_4^{2-} anion is disordered and the geometry around cobalt is distorted tetrahedral. The phenylethyl C atoms of the (4-methoxyphenyl)ethyl group attached to the piperidine ring are disordered, indicating the presence of two conformers in the crystal.

Comment

Astemizole is a potent antihistaminic drug with long-lasting effectiveness and very little or no drowsiness effect (Casy, 1991). Continued interest in the effects of anionic transition metal complexes on the conformation of antihistamines effective on H_1 receptors led to the preparation and crystal structure determination of astemizole tetrachlorocuprate(II) (Parvez & Braitenbach, 2000). In this paper, the structure of astemizole tetrachlorocobaltate(II), (I), is reported; it is isomorphous with the tetrachlorocuprate salt.



The structure is composed of diprotonated astemizole hydrogen-bonded to the tetrachlorocobaltate(II) anion (Fig. 1). The molecular dimensions in the dication are normal and agree well with the corresponding dimensions reported for astemizole tetrachlorocuprate(II) (Parvez & Braitenbach, 2000) and astemizole (Peeters *et al.*, 1995). As in the case of astemizole tetrachlorocuprate(II) (Parvez & Braitenbach, 2000), the phenylethyl C atoms are disordered over C20–C27 and C20'–C27', indicating the presence of two conformers. The methoxy and the piperidinyl groups are not affected by this disorder. The mean plane of the methoxy group is inclined at 25.5 (4) and 7.6 (6)° to the benzene rings C22–C27 and C22'–C27', respectively. The dihedral angle between the mean planes of these benzene rings is 30.8 (3)°. The benzimidazole and fluorophenyl rings are essentially planar and the maximum deviations of atoms from the least-squares planes are 0.026 (4) and 0.013 (4) Å, respectively. The dihedral angle

Received 29 March 2004

Accepted 31 March 2004

Online 9 April 2004




Figure 1
ORTEPII (Johnson, 1976) drawing of the two conformers of (I), with displacement ellipsoids plotted at the 30% probability level; atoms C20'–C27' are shown in green.




Figure 2
ORTEPII (Johnson, 1976) drawing of the contents of a unit cell, showing the hydrogen bonding in (I).

between these planes is $68.04(11)^\circ$. The piperidiny ring adopts a classical chair conformation with puckering parameters (Cremer & Pople, 1975) $Q = 0.582(6) \text{ \AA}$, $\theta = 179.2(6)^\circ$ and $\varphi = 220(22)^\circ$.

The CoCl_4^{2-} anion exhibits a distorted tetrahedral geometry wherein Cl1 is disordered over two sites Cl1 and Cl1' with unequal site-occupancy factors. The hydrogen bonding in (I) is essentially identical to that observed in the isomorphous structure of astemizole tetrachlorocuprate(II) (Parvez & Braitenbach, 2000). The details of the hydrogen-bonding geometry in (I) are given in Table 2.

Experimental

The preparation and crystallization of (I) was achieved following the procedure reported for astemizole tetrachlorocuprate(II) (Parvez & Braitenbach, 2000), resulting in green crystals suitable for crystallographic studies.

Crystal data

$(\text{C}_{28}\text{H}_{33}\text{FN}_4\text{O})[\text{CoCl}_4]$
 $M_r = 661.31$
 Monoclinic, $P2_1/n$
 $a = 9.327(3) \text{ \AA}$
 $b = 15.836(6) \text{ \AA}$
 $c = 20.691(9) \text{ \AA}$
 $\beta = 101.186(14)^\circ$
 $V = 2998(2) \text{ \AA}^3$
 $Z = 4$

$D_x = 1.465 \text{ Mg m}^{-3}$
 Mo $K\alpha$ radiation
 Cell parameters from 9625 reflections
 $\theta = 2.5\text{--}25.0^\circ$
 $\mu = 0.96 \text{ mm}^{-1}$
 $T = 170(2) \text{ K}$
 Prism, blue
 $0.10 \times 0.08 \times 0.06 \text{ mm}$

Data collection

Nonius KappaCCD diffractometer
 ω and φ scans
 Absorption correction: multi-scan (SORTAV; Blessing, 1997)
 $T_{\min} = 0.91$, $T_{\max} = 0.94$
 9625 measured reflections
 5205 independent reflections

2899 reflections with $I > 2\sigma(I)$
 $R_{\text{int}} = 0.084$
 $\theta_{\text{max}} = 25.0^\circ$
 $h = -11 \rightarrow 11$
 $k = -17 \rightarrow 18$
 $l = -24 \rightarrow 24$

Refinement

Refinement on F^2
 $R[F^2 > 2\sigma(F^2)] = 0.065$
 $wR(F^2) = 0.157$
 $S = 1.02$
 5205 reflections
 363 parameters
 H-atom parameters constrained

$w = 1/[\sigma^2(F_o^2) + (0.062P)^2 + 2.13P]$
 where $P = (F_o^2 + 2F_c^2)/3$
 $(\Delta/\sigma)_{\text{max}} < 0.001$
 $\Delta\rho_{\text{max}} = 0.44 \text{ e \AA}^{-3}$
 $\Delta\rho_{\text{min}} = -0.55 \text{ e \AA}^{-3}$

Table 1

Selected geometric parameters (\AA , $^\circ$).

Co1—Cl1'	2.232 (14)	N1—C7	1.397 (7)
Co1—Cl1	2.240 (8)	N1—C8	1.473 (7)
Co1—Cl2	2.257 (2)	N2—C1	1.333 (7)
Co1—Cl4	2.268 (2)	N2—C2	1.397 (6)
Co1—Cl3	2.300 (2)	N3—C1	1.329 (6)
F1—C12	1.367 (8)	N3—C15	1.459 (7)
O1—C25	1.344 (6)	N4—C20'	1.507 (8)
O1—C25'	1.409 (6)	N4—C17	1.489 (7)
O1—C28	1.418 (7)	N4—C18	1.509 (7)
N1—C1	1.353 (6)	N4—C20	1.515 (8)
Cl1'—Co1—Cl2	126.6 (11)	C1—N1—C7	108.2 (4)
Cl1—Co1—Cl2	109.3 (9)	C1—N1—C8	126.2 (5)
Cl1'—Co1—Cl4	102.9 (9)	C7—N1—C8	125.5 (4)
Cl1—Co1—Cl4	112.0 (3)	C1—N2—C2	109.3 (4)
Cl2—Co1—Cl4	105.68 (7)	C1—N3—C15	124.1 (5)
Cl1'—Co1—Cl3	102.7 (4)	C20'—N4—C17	124.4 (8)
Cl1—Co1—Cl3	109.7 (5)	C20'—N4—C18	103.1 (9)
Cl2—Co1—Cl3	104.21 (7)	C17—N4—C18	110.3 (4)
Cl4—Co1—Cl3	115.42 (7)	C17—N4—C20	101.3 (7)
C25—O1—C28	121.6 (7)	C18—N4—C20	119.1 (10)
C25'—O1—C28	113.8 (7)		

Table 2

Hydrogen-bonding geometry (\AA , $^\circ$).

$D\text{---}H\cdots A$	$D\text{---}H$	$H\cdots A$	$D\cdots A$	$D\text{---}H\cdots A$
N2—H2 \cdots Cl2 ⁱ	0.88	2.28	3.154 (5)	170
N3—H3 \cdots Cl3	0.88	2.42	3.212 (5)	150
N4—H4 \cdots Cl4	0.93	2.19	3.109 (5)	171

Symmetry code: (i) $x - 1, y, z$.

The phenylethyl C atoms of the (4-methoxyphenyl)ethyl group attached to the piperidine ring are disordered with essentially equal site-occupancy factors. The benzene ring was restrained as a regular hexagon, with C—C distances of $1.39(1) \text{ \AA}$. Atom Cl1 of the anion is

also disordered over two sites CII and CII' with site-occupancy factors 0.65 (6) and 0.35 (6), respectively. Most of the H atoms were located in difference Fourier syntheses and all were included in the refinements at geometrically idealized positions with C—H = 0.95, 0.98 and 0.99 Å, and N—H = 0.88 and 0.93 Å, and with $U_{\text{iso}}(\text{H}) = 1.5$ (methyl) and 1.2 (the rest) times the U_{eq} of the atoms to which they were bonded. The final difference map was free of any chemically significant features.

Data collection: *COLLECT* (Hooft, 1998); cell refinement: *HKL DENZO* (Otwinowski & Minor, 1997); data reduction: *SCALE-PACK* (Otwinowski & Minor, 1997); program(s) used to solve structure: *SAPI91* (Fan, 1991); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997); molecular graphics: *ORTEPII* (Johnson, 1976); software used to prepare material for publication: *SHELXL97*.

References

- Blessing, R. H. (1997). *J. Appl. Cryst.* **30**, 421–426.
Casy, A. F. (1991). *Histamine and Histamine Antagonists*, edited by B. Uvnas, pp. 549–572. Berlin: Springer-Verlag.
Cremer, D. & Pople, J. A. (1975). *J. Am. Chem. Soc.* **97**, 1354–1358.
Fan, H.-F. (1991). *SAPI91*. Rigaku Corporation, Tokyo, Japan.
Hooft, R. (1998). *COLLECT*. Nonius BV, Delft, The Netherlands.
Johnson, C. K. (1976). *ORTEPII*. Report ORNL-5138. Oak Ridge National Laboratory, Tennessee, USA.
Otwinowski, Z. & Minor, W. (1997). *Methods in Enzymology*, Vol. 276, *Macromolecular Crystallography*, Part A, edited by C. W. Carter Jr and R. M. Sweet, pp. 307–326. New York: Academic Press.
Parvez, M. & Braitenbach, K. (2000). *Acta Cryst.* **C56**, 1216–1217.
Peeters, O. M. Blaton, N. M. & De Ranter, C. J. (1995). *Acta Cryst.* **C51**, 2132–2135.
Sheldrick, G. M. (1997). *SHELXL97*. University of Göttingen, Germany.